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Abstract
Background: The HMGA2 gene encodes a protein that alters chromatin structure. Deregulation,
typically through chromosomal rearrangements, of HMGA2 has an important role in the
development of several mesenchymal neoplasms. These rearrangements result in the expression
of a truncated protein lacking the acidic C-terminus, a fusion protein consisting of the AT-hook
domains encoded by exons 1–3 and parts from another gene, or a full-length protein; loss of binding
sites for regulatory microRNA molecules from the 3' untranslated region (UTR) of HMGA2 has
been suggested to be a common denominator.
Methods: Seventy adipocytic tumors, representing different morphologic and cytogenetic
subgroups, were analyzed by qRT-PCR to study the expression status of HMGA2; 18 of these
tumors were further examined by PCR to search for mutations or deletions in the 3'UTR.
Results: Type (full-length or truncated) and level of expression varied with morphology and
karyotype, with the highest levels in atypical lipomatous tumors and lipomas with rearrangements
of 12q13-15 and the lowest in lipomas with 6p- or 13q-rearrangements, hibernomas, spindle cell
lipomas and myxoid liposarcomas. All 18 examined tumors showed reduced or absent expression
of the entire, or parts of, the 3'UTR, which was not due to mutations at the DNA level.
Conclusion: In adipocytic tumors with deregulated HMGA2 expression, the 3'UTR is consistently
lost, either due to physical disruption of HMGA2 or a shift to production of shorter 3'UTR.
Background
HMGA2 belongs to the high-mobility group A family of
non-histone chromosomal proteins. With its three AT-
hooks it can bind to the minor groove of AT-rich regions
of DNA, affecting the transcription of target genes by
modulating the DNA structure and facilitating or inhibit-
ing the organization of enhanceosomes [1-3]. The
HMGA2 protein has been shown to have important func-
tions in cellular growth and differentiation, with a partic-
ular impact on the progression of the undifferentiated
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out mice display reduced body weight with decreased fat
levels as well as impaired fibroblast proliferation, whereas
transgenic mice expressing activating mutations show
somatic overgrowth with gigantism and lipomatosis [5-7].
Similarly, a boy with a constitutional chromosomal rear-
rangement resulting in deregulation of HMGA2 displayed
a number of features indicative of disturbed mesenchymal
differentiation, such as marked somatic overgrowth, skel-
etal abnormalities and multiple lipomas [8].
Limited studies on the expression patterns of the HMGA2
gene have shown that it is active in most tissues during
fetal development, and that it is transcriptionally silent, or
at least expressed at undetectable levels, in most adult dif-
ferentiated tissues [9]. Aberrant deregulation, however,
has been identified in a number of neoplasms, notably of
mesenchymal origin [2]. In benign mesenchymal tumors,
such as lipoma, the deregulation is often due to a cytoge-
netically visible rearrangement of the HMGA2 locus in
12q15, resulting in the expression of a truncated protein
lacking the acidic C-terminus encoded by exons 4 and 5,
a fusion protein consisting of the AT-hook domains
encoded by exons 1–3 and more or less extensive parts
from another gene, or, less commonly, expression of a
full-length protein; apparently, all three forms – trun-
cated, fusion and full-length – of the HMGA2 protein
have transforming potential when expressed in the rele-
vant cell type [6,7,10-15].
The loss of the C-terminal domains was long thought to
be the cause of neoplastic transformation, but the finding
that some tumor-associated translocations disrupt the 3'-
untranslated region (3'-UTR) instead of the open reading
frame (ORF), resulting in expression of the full-length
HMGA2 protein, suggested that separation of repressive
sequences in the 3'-UTR from the 5'-part of the gene could
be an important mechanism behind transcriptional up-
regulation [12,15,16]. Indeed, the 3'-UTR of HMGA2 is
known to contain multiple binding sites for the let-7 fam-
ily of microRNAs, small non-coding RNAs that inhibit
gene expression at the posttranscriptional level, and it was
recently shown that targeted mutation of these binding
sites as well as functional inactivation of let-7 results in
up-regulation of HMGA2 by reducing HMGA2 mRNA
degradation in the cytoplasm [17,18].
Approximately 75% of conventional lipomas harbor
chromosomal rearrangements of 12q13-15, strongly indi-
cating the involvement of HMGA2 in these cases [19]. The
remaining lipomas display other aberrations, including
recurrent translocations affecting band 6p21, which har-
bors the HMGA1 gene, deletions of 13q, and supernumer-
ary ring chromosomes. The importance of HMGA2
expression in these lipomas and other lipomatous
tumors, remains poorly investigated. Over-expression of
full-length or truncated HMGA2 has been demonstrated
in some lipomas without 12q-rearrangement, as well as in
atypical lipomatous tumors, but no systematic analysis of
the status of HMGA2 in different cytogenetic subsets of
lipomas or in other lipomatous tumors has been per-
formed. In the present study, we used fluorescence in situ
hybridization (FISH) and quantitative RT-PCR (qRT-PCR)
to study the genomic status and expression level of full-
length and truncated HMGA2 in various adipocytic
tumors, including conventional lipomas, angiolipomas,
spindle cell lipomas, hibernomas, atypical lipomas, well-
differentiated liposarcomas, and myxoid liposarcomas.
All cases expressing full-length HMGA2, as well as a few
cases expressing truncated HMGA2 that served as controls,
were further analyzed with regard to mutations in the
3'UTR.
Methods
Patients
A total of 73 adipocytic tumors were selected on the basis
of their histopathologic diagnosis and/or cytogenetic pro-
file. Due to lack of appropriate material, G-banding and
expression analysis of HMGA2 could be performed in
only 69 and 70 cases, respectively. Data concerning
patient age and sex, location and karyotype are shown in
Additional file 1. In brief, the study included five lipomas
with translocation t(3;12)(q27;q13-15), five lipomas
with t(5;12)(q32-33;q14-15), five lipomas with various
other rearrangements of 12q14-15, five lipomas without
any of the known specific cytogenetic hallmarks of
lipoma, five lipomas with structural rearrangement of
6p21-22, five lipomas with deletion of chromosome arm
13q, five lipomas with ring chromosomes, eight angiol-
ipomas, five spindle cell lipomas, five hibernomas, ten
atypical lipomas, five well-differentiated liposarcomas,
and five myxoid liposarcomas.
Cytogenetic analyses
Culturing, harvesting, and chromosome banding of the
tumor cells were performed as previously described [20].
Karyotypes were described according to ISCN (2009) [21].
The karyotypes of 29 samples have been reported before
[19,22-25].
Metaphase FISH analyses
Metaphase FISH was performed on all 18 cases from
which unstained metaphase spreads were available, to
study the status of the HMGA2 gene. BAC clones RP11-
299L9 and RP11-427K2 that span the 5' and 3' ends,
respectively, were used (Figure 1). Five cases had been
analyzed previously [19,25]. Probes were selected through
the UCSC Human Genome Browser genomic maps http:/
/genome.ucsc.edu. Slides were prepared and analyzed and
probes labeled as described elsewhere [26]. When applica-Page 2 of 11
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tral Imaging, Migdal Haemek, Israel) were used to ensure
that tumor cells were analyzed.
DNA and RNA extraction
Total DNA from frozen tumor tissue and peripheral blood
kept at -80°C was extracted using the DNeasy Blood and
Tissue kit according to the manufacturer's recommenda-
tions (QIAGEN, Hilden, Germany). Total RNA from the
same tumor tissue was extracted using the RNeasy Lipid
Tissue Mini kit according to the manufacturer's recom-
mendations (QIAGEN) with minor modifications; 400
mg of tissue were used instead of the recommended 100
mg. After transferring the upper aqueous phase to a new
collection tube, it was spun down once more at 12 000 ×
g for 15 min at 4°C.
cDNA synthesis
Three micrograms of total RNA were reverse transcribed in
a volume of 50 μl for cDNA synthesis, as described previ-
ously [19]. Fetal cDNA from kidney, liver, lung, brain,
heart, spleen, thymus and skeletal muscle (Clontech,
Moutain View, California, USA) were used for RT-PCR.
Quantitative RT-PCR analyses (qRT-PCR)
qRT-PCR was carried out to determine the expression level
of HMGA2. The HMGA2 TaqMan gene expression assays
(Applied Biosystems, Foster City, CA, USA)
Hs00171569_m1 (HMGA2 exons 1–2) and
Hs00971725_m1 (HMGA2 exons 4–5) were used for the
qRT-PCR reaction. Human ACTB was used as endogenous
control for normalization [Human ACTB (beta actin)
Endogenous Control FAM/MGB Probe, Non-Primer Lim-
Schematic illustration of the HMGA2 geneFigure 1
Schematic illustration of the HMGA2 gene. Locations of BAC clones RP11-299L9 (FITC) and RP11-427K2 (Cy3) and 
primers for the qRT-PCR reaction for exons 1–2 (FEx 1–2: forward primer and REx 1–2: reverse primer) and exons 4–5 (FEx 4-5: 
forward primer and REx 4-5: reverse primer) are indicated. The lower part shows an enlargement of the 3'UTR, where the base 
pair positions are based on the nucleotide sequence of NM_003483. Reported (Lee and Dutta, 2007) binding sites for let-7 are 
shown as dark boxes. Regions 1, 2 and 3 represent the sequences amplified by PCR; the locations of forward (F) and reverse 
(R) primers for each region are indicated. For details regarding primers, see Additional file 3.
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replicates of each sample and endogenous control were
performed. For the commercial assay we had 1×TaqMan
universal Mix, l× of the 20×TaqMan gene expression mix
and 3 μl cDNA, in a volume of 20 μl. The PCR was run on
a 7500 real-time PCR System (Applied Biosystems) using
the standard 7500 run mode. The PCR conditions were 2
min at 50°C and 10 min at 95°C, followed by 50 cycles at
95°C for 15 sec, and 1 min at 60°C. The SDS software
1.3.1 (Applied Biosystems) was used to analyze data. The
comparative threshold cycle (Ct) method was used to
achieve relative quantification of RNA expression [27]: the
value of the target, normalized to an endogenous control
(ACTB) and relative to a calibrator, was expressed as 2-ΔΔCt
(fold difference), where ΔCt of the target gene samples
minus the ΔCt of the target gene calibrator gives the ΔCt
value of the target message [27]. Total RNA from human
adipose tissue (Ambion's total Human RNA, Austin, TX,
USA) was the calibrator for cDNA control. Expression
cycles for exons 1–2 and 4–5 of HMGA2 in human adi-
pose tissue are illustrated, see Additional file 2.
Genomic PCR, RT-PCR and Sequence analyses
PCR and sequencing were performed to study cryptic dele-
tions and point mutations in the HMGA2 3'UTR, harbor-
ing the target sites of the let-7 miRNA family (Figure 1), in
18 tumors. These cases included all nine tumors with full-
length HMGA2 expression and from which further mate-
rial was available, as well as controls showing differential
or weak expression of HMGA2. The PCR reaction was per-
formed as described [19]. The PCR products were ana-
lyzed on 2–2.5% agarose gels. Primers used for
sequencing are listed in Additional file 3. All transcripts
identified were verified by sequencing, and the corre-
sponding nucleotide sequences were analyzed using the
Chromas software http://www.technelysium.com.au/
chromas.html. The HMGA2 origin of the sequences was
verified by BLAST search http://www.ncbi.nlm.nih.gov/
blast. Sequence data on HMGA2 were obtained from the
sequence of the clone with accession number
NM_003483 [GenBank:NM_003483]. Polymorphisms
were identified from the ensembl database http://
www.ensembl.org.
Results
Cytogenetics and FISH
Sixty-nine of the 73 cases were analyzed by G-banding;
from four of the cases no short-term cultures were availa-
ble. Metaphase FISH analysis regarding the status of the
HMGA2 gene was performed on 18 cases (Additional file
1). In brief, of four analyzed lipomas with t(5;12)(q32-
33;q14-15), two displayed normal signals for the HMGA2
gene, one showed a split signal, and one showed translo-
cation of the entire HMGA2 gene to chromosome 5 (Fig-
ure 2A). Of four lipomas with various aberrations
affecting 12q13-15, three had split signals and one had a
deletion of the 3'-end of the gene (Figure 2C and 2D). Of
three lipomas without any of the recognized cytogenetic
hallmarks of lipoma two had normal signals and one a
deletion of the 3'-end of the gene. The only analyzed
lipoma with a translocation involving 6p21-22 and two
angiolipomas had normal signals for HMGA2. Four atyp-
ical lipomas with ring chromosomes showed amplifica-
tion of HMGA2, with more copies of the 5'-end than of
the 3'-end; intact signals were consistently found on the
normal chromosomes 12 (Figure 2B).
qRT-PCR
A total of 70 adipocytic tumors were investigated with
qRT-PCR for the expression of HMGA2 exons 1–2 and
exons 4–5. Aberrant expression of HMGA2 was defined as
a Log10 value of > 1 for exons 1–2 and/or 4–5; expression
levels > 10 times higher for exons 1–2 than for exons 4–5
are hereafter referred to as differential expression. Using
these criteria, aberrant expression was seen in 47 cases, of
which 24 showed differential expression (detailed results
in Additional file 1). None of the cases showed aberrant
expression of exons 4–5 without simultaneous aberrant
expression of exons 1–2. In brief, the expression levels of
exons 1–2 were highest among well-differentiated liposa-
rcomas (median Log10 value of 3.55), followed by atypi-
cal lipomas (3.46), t(5;12)-lipomas (3.13), t(3;12)-
lipomas (3.00), conventional lipomas with ring chromo-
somes (2.80), lipomas with various rearrangements of
12q13-15 (2.65), lipomas without any of the recognized
cytogenetic hallmarks of lipoma (1.85), angiolipomas
(1.10), del(13q)-lipomas (0.74), lipomas with rearrange-
ments of 6p21 (0.13), myxoid liposarcomas (0.11), spin-
dle cell lipomas (-0.09), and hibernomas (-0.53).
Individual expression levels are illustrated in Figure 3.
With regard to the number of cases showing aberrant and
differential expression, the results were as follows: of 15
lipomas with cytogenetic rearrangement of 12q13-15 all
showed aberrant expression, with differential expression
in all five lipomas with t(3;12), one of five lipomas with
t(5;12)(q32-33;q14-15), and three of five lipomas with
various other rearrangements of 12q13-15. Four of five
lipomas without any of the recognized cytogenetic hall-
marks of lipoma showed aberrant expression, with differ-
ential expression in two. One of five lipomas with
rearrangement of 6p21-22 showed differential expression,
and of five lipomas with del(13q), two showed aberrant
expression with differential expression in one. All 20
lipomatous tumors with ring chromosomes showed aber-
rant expression, with differential expression in two of five
conventional lipomas, six of ten atypical lipomas, and
two of five well-differentiated liposarcomas. Three of five
angiolipomas showed aberrant expression, without any
sign of differential expression. None of the five myxoidPage 4 of 11
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lipoma (differential expression) and hibernoma (full-
length) showed aberrant expression.
RT-PCR and genomic PCR
The expression of the reported 3'UTR of HMGA2, divided
into three regions covering all eight known binding sites
for let-7, was studied by RT-PCR in 18 tumors, various
fetal tissues and amniocytic cell cultures (Table 1). Of the
18 tumors, nine had aberrant expression of both exons 1–
2 and 4–5, four showed differential expression of exons
1–2, two showed weak expression of both exons 1–2 and
4–5, and three had unknown expression status. All three
amniocytic cell cultures expressed all three regions of the
3'UTR (see Additional file 4A). In the fetal tissues, expres-
sion of Region 1 was found in kidney, liver, lung, spleen,
and thymus, but the bands were weak except in kidney.
Expression of regions 2 and 3 was seen in all tissues except
brain, which also lacked expression of region 1 (see Addi-
tional file 5A). Of the tumors, only one (case 10)
expressed all three regions, but with very weak expression
of region 2. Faint bands for region 1 and/or 3 were seen in
nine tumors. In the remaining eight tumors, including
two cases with differential expression of HMGA2, none of
the regions was detected (Table 1, see Additional file 4A).
Genomic PCR for the 3'UTR of HMGA2 was performed in
Metaphase FISH on four cases regarding the involvement of the HMGA2 geneFigure 2
Metaphase FISH on four cases regarding the involvement of the HMGA2 gene. BAC clones RP11-299L9 (FITC) and 
RP11-427K2 (Cy3), spanning the 5' and 3' parts, respectively, of HMGA2 were used. Arrowheads indicate normal chromo-
somes 12 A) Lipoma (case 10) with a t(5;12)(q33;q14) where the entire HMGA2 locus was translocated to chromosome 5. A 
wcp5 probe was used to identify chromosome 5 in tumor cells. The derivative chromosome 12 was present in the metaphase 
cell, but not included in the picture B) Atypical lipoma (case 55) with ring chromosome and amplification and split signal of 
HMGA2. Normal signals for HMGA2 can be seen on the two normal chromosomes 12. C) Lipoma (case 11) with an 
inv(12)(q14q24) causing a deletion of the 3'-end of HMGA2; thus, only the green signal corresponding to RP11-299L9, covering 
the 5'-part, can be seen. D) Lipoma (case 14) with a t(10;12)(q22;q15) resulting in a split signal for HMGA2; the 3' part of the 
gene is translocated to chromosome 10. A wcp12 was used to identify chromosome 12 in tumor cells.
D
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addition, DNA from peripheral blood was available from
six of the cases. PCR products of expected size were seen
in all tumors and blood samples (see Additional files 4B
and 5B).
Sequencing
Sequencing of the 3'UTR of HMGA2 was performed on
the 15 tumors in which genomic PCR was conducted to
study involvement of the let-7 binding sites. As reference,
the sequence with accession number NM_003483 was
used [GenBank NM_003483]. In region 1, eight of the 15
tumors were homozygous for G/G, six homozygous for T/
T and one heterozygous for T/G for a previously reported
polymorphism in position 1280 (reference number
rs3741427). In region 2, one tumor was homozygous for
C/C, two were homozygous for T/T, and 12 were hetero-
zygous for C/T at position 2416 (reference number
rs1042725). In region 3, no mutations were seen.
Discussion
Among the 35 conventional lipomas that were analyzed
here, four expression patterns were observed: (1) strong
(>100-fold) expression of the full-length gene (exons 1–2
as well as 4–5) or (2) a truncated gene (only exons 1–2;
differential expression), (3) moderate (10–100-fold)
expression of the entire gene, and (4) weak/absent expres-
sion of any part of the gene. Although we cannot fully
exclude that low expression in some case was due to
admixture of normal cells, it is of interest to note that the
Expression patterns (log10 scale) of exons 1–2 and exons 4–5 of HMGA2 in lipomatous tumorsFigure 3
Expression patterns (log10 scale) of exons 1–2 and exons 4–5 of HMGA2 in lipomatous tumors. A) Seven different 
cytogenetic subgroups of conventional lipoma: lipomas with t(3;12)(q27;q13-15), lipomas with t(5;12)(q32-33;q14-15), lipomas 
with various other rearrangements of 12q14-15, lipomas without any of the known cytogenetic hallmarks of lipoma, lipomas 
with structural rearrangement of 6p21-22, lipomas with deletion of chromosome arm 13q, and lipomas with ring chromo-
somes. B) Six other subtypes of lipomatous tumor: angiolipomas, spindle cell lipomas, hibernomas, atypical lipomas, well-differ-
entiated liposarcomas, and myxoid liposarcomas. The case numbers correspond to the case numbers in Additional file 1.Page 6 of 11
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group. All five lipomas with t(3;12) showed strong (log10
ratio between 2.72 and 3.15), differential expression. The
t(3;12) is the most common cytogenetic aberration in
conventional lipoma, resulting in an HMGA2/LPP fusion
gene. In cases reported in the literature, the fusion gene
always contains exons 1–3 of HMGA2 and, usually, exons
9–11 of LPP, which is at odds with the finding of
increased (log10 ratios 1.04 and 1.49) expression of exons
4–5 in two of our cases. However, a few reported lipomas
with t(3;12) have also expressed the reciprocal LPP/
HMGA2 chimera and some tumors with rearrangements
of HMGA2 express the wild type allele [14,28-31].
In contrast, only one of five lipomas with a t(5;12), the
second most common translocation in conventional lipo-
mas, showed differential expression in the present study;
the other four cases all showed aberrant expression of the
entire gene. This is in line with previous FISH data on this
particular translocation, demonstrating that the genomic
breakpoints usually occur outside the HMGA2 locus [25].
The only case here with differential expression also had a
split HMGA2 locus at FISH analysis, supporting the view
that the molecular outcome of the t(5;12) is heterogene-
ous. Cytogenetic analyses of conventional lipomas have
identified numerous other translocation partners to the
HMGA2 locus in 12q [19]. Although only a few of these
partners have been examined at the molecular level, it is
well known from FISH studies that the breakpoints may
occur inside as well as outside HMGA2. Thus, it was not
unexpected that all five lipomas with variant 12q13-15
rearrangements in the present study, representing five dif-
ferent recombination partners, showed overexpression of
HMGA2 and that some of them had expression of the full-
length gene whereas others had differential expression.
Interestingly, strong expression of the full-length gene was
seen in one case with a t(1;12)(p32;q15) and a split FISH
signal, with the 3'-part of HMGA2 translocated to chro-
mosome 1. Combined, these findings indicate that this
particular translocation led to the fusion of HMGA2 with
a strongly expressed gene in chromosome 1. However,
high expression of the other, wild type, allele cannot be
excluded.
The molecular pathways in conventional lipomas with
rearrangements of 6p or deletions of 13q remain to be
Table 1: RT-PCR and genomic PCR analyses of the 3' UTR of HMGA2
RT-PCR products Region Genomic PCR products Region
Case Sample Type of HMGA2 expression 1 2 3 1 2 3
Amniocytes 1 ND + + + ND ND ND
Amniocytes 2 ND + + + ND ND ND
Amniocytes 3 ND + + + ND ND ND
4 Lipoma t(3;12) Differential (+) - (+) + + +
4 Peripheral blood ND ND ND ND + + +
10 Lipoma t(5;12) Aberrant + (+) + + + +
11 Lipoma der(12q13-15) Differential - - - + + +
13 Lipoma der(12q13-15) Aberrant - - - + + +
17 Variant Lipoma Aberrant (+) - (+) + + +
18 Variant Lipoma Aberrant (+) - - + + +
18 Peripheral blood ND ND ND ND + + +
21 Lipoma der(6p21-22) Differential - - (+) ND ND ND
26 Lipoma del(13q) Differential - - - + + +
26 Peripheral blood ND ND ND ND + + +
27 Lipoma del(13q) Aberrant - - - ND ND ND
36 Angiolipoma Aberrant (+) - + ND ND ND
37 Angiolipoma Aberrant - - (+) + + +
38 Angiolipoma Aberrant - - (+) + + +
38 Peripheral blood ND ND ND ND + + +
39 Angiolipoma Weak - - - + + +
39 Peripheral blood ND ND ND ND + + +
40 Angiolipoma Weak - - - + + +
40 Peripheral blood ND ND ND ND + + +
41 Angiolipoma ND - - - + + +
42 Angiolipoma ND - - (+) + + +
43 Angiolipoma ND - - - + + +
49 Hibernoma Aberrant - - (+) + + +
Abbreviations: Aberrant = Log10 value of ≥ 1 for exons 1–2 and exons 4–5; Differential = Aberrant expression of exons 1–2 with ≥ 10 times higher 
expression than for exons 4–5; Weak = Log10 value 0–1 for exons 1–2 and 4–5; + = strong PCR product; (+) = weak PCR product; - = no PCR 
product; ND = not determined.Page 7 of 11
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the HMGA1 gene, located in band 6p21, could substitute
for HMGA2 rearrangements, but this has been verified in
only a small number of cases, [19,32-34] and no candi-
date target for 13q-deletions has been identified. The
notion that the molecular pathogenesis of these lipomas
is different from that in 12q-positive ones was strength-
ened by the finding here that only one case in each group
showed strong HMGA2 expression. Further, indirect sup-
port for the hypothesis that most lipomas with 6p21 or
13q-rearrangements develop through pathways that do
not involve HMGA2 could be found among the lipomas
that showed aberrations that do not belong to any of the
known cytogenetic subgroups of conventional lipomas;
four of five showed aberrant (log10 ratio 1.80–2.17)
expression of the 5'part or of the entire gene. Thus, most
of the non-recurrent cytogenetic aberrations observed are
probably secondary changes, accrued during tumor
growth.
Ring chromosomes and giant markers (hereafter referred
to as rings) constitute the cytogenetic hallmark of atypical
lipomatous tumors, and it has been shown that these
rings consistently contain amplified sequences from chro-
mosome 12 [35-38]. Occasionally, also tumors diagnosed
as conventional lipoma display rings, and it has been
debated whether these cases represent highly differenti-
ated atypical lipomatous tumors or whether some are true
conventional lipomas with a similar genetic profile
[19,36,39-42]. The former interpretation seems the more
likely; not only do tumors diagnosed as conventional
lipomas with rings share the clinical characteristics of
atypical lipomatous tumors (male predominance, larger
size, preferential location in the thigh), but the genomic
contents of the rings are the same [42-44]. In the present
study, the expression of HMGA2 was increased (full-
length in three and differential in two) in all five cases
diagnosed as conventional lipomas with rings. However,
the expression levels (median log10 ratio for exons 1–2,
2.80) were more similar to those seen in lipomas with
t(3;12) and t(5;12) (median log10 ratios 3.00 and 3.13,
respectively) than in tumors diagnosed as atypical lipo-
mas and well-differentiated liposarcomas (median log10
ratios 3.46 and 3.55, respectively), whereas the fraction of
lesions with differential expression was similar in all three
tumor entities. This raises the interesting possibility that
the level of cellular atypia may be influenced by the level
of HMGA2 expression in lipomatous tumors with rings.
However, the rings are highly complex chromosome aber-
rations and it cannot be excluded that the amplification
and expression levels of other genes influence the pheno-
type.
Whereas atypical lipomatous tumors in the extremities
seldom recur after surgery and only rarely transform into
high-grade lesions, morphologically and cytogenetically
identical lesions in the retroperitoneum commonly dedif-
ferentiate, eventually often killing the patient. To empha-
size these differences in clinical behaviour, the former are
often referred to as atypical lipomas, and the latter as well-
differentiated liposarcomas. In the present study, we ana-
lyzed ten atypical lipomatous tumors of the extremities
and five of the retroperitoneum. They consistently
showed high expression of HMGA2, arguing for the
importance of deregulated HMGA2 expression also in this
subtype of lipomatous tumors [36,45].
Taken together, these results demonstrate that all 35
lipomatous tumors with cytogenetically visible 12q13-15
rearrangements – translocations, inversions, rings – have
aberrant expression of HMGA2, and that some of these
rearrangements, like the t(3;12), consistently result in dif-
ferential expression of the first three exons whereas other
rearrangements, like the t(5;12), most often lead to
expression of the entire gene. The lack of HMGA2 expres-
sion in most cases with rearrangements of 6p21 or dele-
tions of 13q strongly support the view that these lipomas
develop through other genetic pathways. The consistently
high expression of HMGA2 in conventional lipomas with
ring chromosomes provides further support for the idea
that these tumors belong to the same biologic entity as
atypical lipomas and well-differentiated liposarcomas.
As expected, none of the five myxoid liposarcomas, which
all had a t(12;16) resulting in a FUS-DDIT3 fusion gene
(data not shown), expressed HMGA2. Similarly, most
hibernomas and spindle cell lipomas, which at the chro-
mosome level typically show translocations affecting
chromosome band 11q13 and deletions of 13q, respec-
tively, did not show any deregulation of HMGA2. How-
ever, one case each demonstrated moderate expression of
the full-length gene (hibernoma, log10 ratio exons 1–2,
1.60) or only of the amino-terminal part (spindle cell
lipoma, log10 ratio exons 1–2, 1.76). Although both cases
were morphologically typical, it is well known that hiber-
nomas and spindle cell lipomas may contain more or less
extensive areas resembling conventional lipomas, pre-
sumably reflecting differentiation. Possibly, such areas
might be associated with deregulated expression of
HMGA2.
Angiolipomas often occur as multiple tumors, and an
autosomal dominantly inherited predisposition is appar-
ent in some families [46,47]. Repeated cytogenetic analy-
ses have, with a single exception, resulted in normal
karyotypes [23], suggesting that they are either non-neo-
plastic or that they arise through submicroscopic muta-
tions [46]. In the present study, five cases could be
analyzed with regard to expression level of HMGA2, two
of which were also studied by FISH; none of the latterPage 8 of 11
(page number not for citation purposes)
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In all cases, the expression levels were highly similar for
exons 1–2 and 4–5, and the median expression level
(log10 ratio 1.10 for exons 1–2) was higher than that in
myxoid liposarcomas, hibernomas, spindle cell lipomas,
and lipomas with 13q-deletions or 6p21-rearrangements,
but lower than that in conventional lipomas with cytoge-
netically visible 12q-rearrangements. Thus, it seems as if
also angiolipomas, at least to some extent, are associated
with aberrant HMGA2 expression, but not on the basis of
gross chromosomal rearrangements.
To study the role of the 3'UTR for deregulated HMGA2
expression, RT-PCR was performed in 18 lipomatous
tumors, including nine with aberrant expression of the
full-length gene, four with differential expression, and five
with weak or unknown expression (Table 1). The 3'UTR of
HMGA2 is 2996 bp long, according to the sequence
reported in 1996 by Ashar et al. [Gen-
Bank:NM_003483][48]. It contains a number of potential
termination sites before the one that ends the reported
full-length UTR. In addition, there are 10 AUUUA ele-
ments, which are thought to be important for deadenyla-
tion and subsequent decay of the mRNA [15]. We are not
aware of any previous, systematic in vivo studies of the
expression of the 3'UTR, neither in tumors nor in non-
neoplastic tissues, but several experimental studies have
suggested that the 3'UTR plays an important role in the
posttranscriptional regulation of HMGA2. In 2001, Bor-
rmann et al. measured the luciferase activity of the full-
length and five different deletion constructs of the
HMGA2 3'UTR [15]. They found that truncation of the
distal 593 bp reduced the activity, suggesting the existence
of positive regulatory elements at the 3' end of the UTR,
but that further deletions significantly increased the luci-
ferase activity. This increase was interpreted to be due to
the loss of the AUUUA elements. More recently, it was
shown that the 3'UTR of HMGA2 contains eight, func-
tional or putative, binding sites for the let-7 family of
microRNAs, and that mutational inactivation of these
binding sites increased the mRNA levels of HMGA2
[17,18,49,50]. In line with these findings, it is known that
let-7 and HMGA2 expression levels are inversely correlated
during embryogenesis. This agrees well with the strong
expression of the entire 3'UTR in all three amniocytic cell
cultures included here. In contrast, only two of the
tumors, a lipoma with t(5;12) and a relocated HMGA2
locus and an angiolipoma, showed convincing expression
of any of the three regions. The remaining tumors, regard-
less of morphologic subtype and type of HMGA2 expres-
sion, showed only faint expression of no more than two
of the three regions investigated, providing further in vivo
support for the notion that loss of regulatory sequences
from the 3'UTR is essential for aberrant expression of
HMGA2 in lipomatous tumors. However, as loss or signif-
icant reduction of expression of the 3'UTR was a consist-
ent feature also of tumors with expression of the full-
length gene and normal HMGA2 loci at FISH analysis,
there must be other mechanisms than chromosomal rear-
rangements leading to this transcriptional silencing. It was
recently shown by Sandberg et al. (2008) that proliferat-
ing cells tend to shift from producing longer to shorter
mRNA isoforms, and they suggested that a switch to more
proximal polyadenylation sites might be a mechanism for
these cells to escape regulation by microRNAs [51]. How
this shift from expressing mRNAs with full-length 3'UTR,
as seen in the amniocytic cultures, to mRNAs without the
3'UTR, or at least with a 3'UTR too short to be detected by
the assays used here, is achieved in lipomatous tumors
remains to be clarified. Our and others results indicate
that the expression of HMGA2 [9,52] as well as its 3'UTR
varies from one tissue to another. Based on the present
study, however, the lack of 3'UTR expression seems not to
be due to mutations within the 3'UTR itself. Furthermore,
nor could we find any evidence that a SNP (rs1042725)
within the 3'UTR that has been associated with body
height [53] has any impact on the development of
lipomatous tumors.
Conclusion
We have shown that the expression (level and/or type of
transcript) of HMGA2 in adipocytic tumors varies with
morphologic subtype and cytogenetic background. Thus,
transcriptional deregulation was strongly associated with
cytogenetically visible involvement of the HMGA2 locus.
We also showed that tumors expressing HMGA2 do not
express the 3'UTR of the gene, thereby avoiding down-reg-
ulation by the let-7 family of microRNAs.
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